Therapeutic Workshop
Cardiovascular Disease: Not for the Faint-Hearted
Thursday, October 20
8:15 a.m. - 9:15 a.m.
Presidio
Cardiovascular remains a huge market with significant unmet medical needs. Yet with the safety requirements in this post-Vioxx environment, is the bar too high for biotech companies to bring a product through clinical studies and to the patient? How does biotech innovation take place in this environment? Industry and clinical experts discussed different strategies for developing important new cardiovascular compounds, the latest thinking on relevant clinical endpoints, as well as the requirements for successful trial design at each stage of clinical development based on what we know today.
Moderator:
- George F. Schreiner, MD, PhD, President, Research & Development, Scios Inc., a Johnson & Johnson company
Panelists:
- Michael R. Bristow, MD, PhD, Professor of Medicine, Division of Cardiology, University of Colorado Health Sciences Center
- Kenneth E. Drazan, MD, Chief Executive Officer & President, Arginox Pharmaceuticals, Inc.
- Jason Kantor, PhD, Managing Director and Biotechnology Equity Research Analyst, RBC Capital Markets Corporation
- Fady Malik, MD, PhD, FACC, Director, Cardiovascular Programs, Cytokinetics, Inc.
- David Phillips, PhD, Senior Vice President, Biology, Portola Pharmaceuticals, Inc.